Navigation Links
Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
Date:2/26/2008

2008, at 3 pm CET. The dial-in numbers are:

+41(0)91-610-56-00 (Europe)

+44(0)207-107-0611 (UK)

+1(1)-866-291-4166 (USA)

The conference call (Call ID 16607, followed by the #) will be available

for play-back for 48 hours after the call by dialling:

+41(0)91-612-43-30 (Europe)

+44(0)207-108-6233 (UK)

+1(1)866-416-2558 (USA)

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial close to NDA-filing and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent late-stage antibiotic that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been completed. The NDA-filing process for intravenous iclaprim in this indication in the USA is ongoing and expected to be completed in the next few weeks.

In December 2007, Arpida announced the enrolment of the first patients in a Phase II clinical study with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch should be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's f
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. CardioDynamics Provides 2007 Shareholder Meeting Update
10. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
11. NxStage Medical Provides Update on Medisystems Acquisition
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... 2015  Roka Bioscience, Inc. (NASDAQ: ROKA ... advanced testing solutions for the detection of foodborne ... three months and full year ended December 31, ... for the quarter ended December 31, 2014 was ... quarter of 2013 and $1.5 million for the ...
(Date:3/26/2015)... 2015 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" or the ... with certain matters, including the appointment of auditors, its ... 26, 2015 (the "Meeting") was adjourned, as previously disclosed ... 11:00 a.m. ( Toronto time). The ... that previous disclosed. The Meeting will reconvene at the ...
(Date:3/26/2015)... 2015  BioNano Genomics, Inc., the leader in genome ... as chief commercial officer. Salyer has more than 20 ... in life sciences. At BioNano, Salyer will oversee the ... platform to assemble a comprehensive view of complex genomes ... 32 institutions located in the United States ...
(Date:3/26/2015)... March 26, 2015 Neogen Corporation (NASDAQ: ... the third quarter of fiscal 2015, which ended Feb. ... prior year,s $6,575,000. Earnings per share in the current ... Current year-to-date net income increased 17% over prior year ... or $0.56 per share, for the same period a ...
Breaking Biology Technology:Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 2Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 3Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 4Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 5Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 6Roka Bioscience Reports Fourth Quarter and Full Year 2014 Financial Results 7SQI Diagnostics Inc. Announces Adjournment of Meeting 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 2BioNano Genomics Appoints Terry Salyer as Chief Commercial Officer 3Neogen reports 13% increase in net income 2Neogen reports 13% increase in net income 3Neogen reports 13% increase in net income 4Neogen reports 13% increase in net income 5Neogen reports 13% increase in net income 6Neogen reports 13% increase in net income 7Neogen reports 13% increase in net income 8
... Sinovac Biotech Ltd. (Amex: SVA ),a leading provider ... CEO, and Ms. Helen Yang, International Business Manager, are ... All-Cap All-China Conference,on Monday, May 19, 2008 at 10:15 ... York, NY., Ms. Nan Wang, Vice President, and ...
... Calif., May 7 Jazz,Pharmaceuticals, Inc. (Nasdaq: JAZZ ... 2008 financial results on May 13, 2008, following the,close ... an,investor conference call and live audio webcast to discuss ... 5:00 p.m. Eastern Time/2:00 p.m.,Pacific Time., The live ...
... Mammography Revenue Growth and FDA Approval of Fujifilm CAD,Product Expected to Drive Growth ... ... Conference ... iCAD, Inc. (Nasdaq:,ICAD), an industry-leading provider of Computer-Aided Detection (CAD),solutions for the early ...
Cached Biology Technology:Sinovac to Present at the Brean Murray, Carret & Co. All-Cap All-China Conference and the Roth China Discovery Tour 2008 2Jazz Pharmaceuticals, Inc. to Announce First Quarter Results on May 13, 2008 2iCAD Reports First Quarter 2008 Financial Results 2iCAD Reports First Quarter 2008 Financial Results 3iCAD Reports First Quarter 2008 Financial Results 4iCAD Reports First Quarter 2008 Financial Results 5iCAD Reports First Quarter 2008 Financial Results 6iCAD Reports First Quarter 2008 Financial Results 7iCAD Reports First Quarter 2008 Financial Results 8iCAD Reports First Quarter 2008 Financial Results 9
(Date:3/11/2015)... and Markets ( http://www.researchandmarkets.com/research/3p32qm/access_control ) has announced ... Product, Application & By Geography - Global Forecast & ... This report predicts that the access control ... with an estimated CAGR of 10.6%. The ... as contact cards & readers, contactless cards & readers, ...
(Date:3/10/2015)... Transforming How We Look at ... in Human Space Flight" by Michael A. ... Ph.D. was recently featured by Springer Science Media, highlighting the ... Specifically, "Personalized Medicine in Human Space Flight" was ... 2013 and 2014 from Springer in the journal ...
(Date:3/5/2015)... PAULO , March 5, 2015 In ... 41 percent of companies already using these solutions and 42 ... 2015. Of the latter, approximately 25 percent of the companies ... While the majority of companies in the region ... anticipated that the hybrid model will command significant attention in ...
Breaking Biology News(10 mins):Global Access Control (Cards & Readers, Biometrics, Controllers, Management Software) Market 2015-2020 - Analysis of the $10 Billion Market 2"Personalized Medicine in Human Space Flight" Listed Among Most Influential Papers of 2013 and 2014 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4
... D.C. The evolution of complex life forms may have ... events operating over millions of years caused large quantities of ... proposed in a new paper by Dominic Papineau of the ... have caused vast algal blooms, pumping extra oxygen into the ...
... EVANSTON, Ill. --- How do children reason about ... between human and non-human animals? For decades, the ... the biological world, they adopt an "anthropocentric" stance, favoring ... about properties of animals. But Northwestern University ...
... Even healthy pregnant women can be at risk for ... Reserve University began to understand which bacteria from the 700 ... health problem of preterm and stillbirths. Yiping Han ... Dental Medicine led the study, which found several new bacteria ...
Cached Biology News:Did phosphorus trigger complex evolution -- and blue skies? 2Animals talk, sing and act like humans? 2Even healthy pregnant women need to worry about oral bacteria 2